Introduction
The epidermal growth factor receptor (EGFR) is overexpressed in many human epithelial tumors, either as a consequence of gene amplification or by increased mRNA production (Gullick, 1991) . Increase in EGFR expression levels is often correlated with a poor clinical prognosis (Grandis et al., 1998; Korshunov et al., 1999) . In glioblastoma multiforme, 37-58% of tumors with EGFR gene amplification also contain gene rearrangements (Kuan et al., 2001) with the most common mutation, the de2-7 EGFR, leading to a specific deletion between exons 2-7 of the EGFR gene (Sugawa et al., 1990; Ekstrand et al., 1991; Kuan et al., 2001) . Apart from glioma, the de2-7 EGFR has been reported in breast, non-small-cell lung, ovarian and prostate cancer (Garcia de Palazzo et al., 1993; Moscatello et al., 1995; Olapade-Olaopa et al., 2000) , but not in normal tissue . The truncation of exons 2-7 leads to the elimination of 267 amino acids from the extracellular domain and renders the mutant EGFR unable to bind any known ligand (Wikstrand et al., 1998) . Despite this, the de2-7 EGFR displays a low level of constitutive activation, which is enhanced by its reduced capacity for internalization (Huang et al., 1997) .
Glioma and breast cancer cell lines transfected with the de2-7 EGFR have enhanced tumorigenicity when grown as xenografts in nude mice (Nishikawa et al., 1994; Tang et al., 2000) , but the receptor has very little effect on in vitro growth (Nishikawa et al., 1994) . While the increased tumorigenicity mediated by the de2-7 EGFR is primarily due to the receptor's constitutive tyrosine kinase activity (Huang et al., 1997) , attempts to identify intracellular molecules involved in mediating de2-7 EGFR signalling have been inconclusive. The introduction of the de2-7 EGFR into NIH3T3 murine fibroblasts led to an elevation in phosphatidylinositol 3-kinase (PI3-K) levels, which was found to enhance both monolayer and anchorage-independent cell growth (Moscatello et al., 1998) . Similarly, transfection of the de2-7 EGFR in U87MG human glioma cells led to an increase in PI3-K activity (Lorimer and Lavictoire, 2001) . Indeed, two very recent papers have confirmed that PI3-K activity is important to the growth advantage mediated by the de2-7 EGFR in U87MG cells (Narita et al., 2002; Klingler-Hoffmann et al., 2003) . However, as both U87MG and NIH3T3 cells endogenously express the wt EGFR, it is not known if the de2-7 EGFR can directly activate PI3-K alone in the absence of the wt receptor. The activation of mitogen-activated protein kinase (MAPK) by de2-7 EGFR also remains unclear. Montgomery et al. (1995) originally reported low levels of de2-7 EGFR-mediated MAPK activity in NIH3T3 cells, but later suggested that there was no activation in the same cell line (Moscatello et al., 1996) . Likewise, no activation of MAPK in NR6 cells, a variant of NIH3T3 that does not express the wt EGFR, following transfection with de2-7 EGFR was observed (Chu et al., 1997) . In contrast, Wu et al. (1999) did report activation of MAPK in NR6 cells. Two groups have reported that MAPK is activated by de2-7 EGFR in U87MG glioma cells (Wu et al., 1999; Lorimer and Lavictoire, 2001) . Therefore, which intracellular molecules significantly contribute to the in vivo enhanced tumorigenicity of de2-7 EGFR remains unclear.
There are two major difficulties associated with analysing the de2-7 EGFR-activated pathways in cancer cells. Firstly, the growth advantage conferred by de2-7 EGFR is predominantly restricted to in vivo growth, making detailed analysis more difficult. Secondly, most cancer cell lines express other members of the ErbB family that are potentially capable of forming heterodimers with the de2-7 EGFR (O'Rourke et al., 1998) , obscuring the signalling events exclusively associated with the mutant receptor. While in in vitro studies with NR6 cells, a NIH3T3 derivative cell line devoid of wt EGFR, the effects of de2-7 EGFR are only observed at extremely high levels of expression. Therefore, we used the interleukin-3 (IL-3)-dependent murine, pro-Bcell line, BaF/3 (Palacios and Steinmetz, 1985) , which does not express any of the ErbB family members, to analyse the biological effects mediated by de2-7 EGFR expression when expressed at moderate levels.
Results

Selection of BaF/3 cells expressing high de2-7 EGFR levels
To examine the biological effects of the de2-7 EGFR, the de2-7 EGFR gene was transfected into BaF/3 cells. Expression of the de2-7 EGFR in the transfected cells was confirmed by FACS analysis (Figure 1a ) and this population designated as BaF/3.D2-7
À0
. To determine whether the de2-7 expression promoted proliferation and/or survival in the absence of IL-3, cells were cultured in the absence of IL-3 for 96 h. Visual examination following trypan blue staining revealed that while all parental cells had died, a small percentage (3-5%) of BaF/3.D2-7 cells remained viable. Viable cells were expanded by replenishment with IL-3, and analysed again for de2-7 EGFR. Average expression of de2-7 EGFR was considerably higher in this cell population compared with the original transfected population (Figure 1a ). This new cell population (BaF/ 3.D2-7
À1
) was cultured again in the absence of IL-3 for 96 h and the surviving cells expanded. Analysis of this final cell population (BaF/3.D2-7
À2
) revealed a further increase in the mean de2-7 EGFR expression level ( Figure 1a) . Thus, BaF/3 cells expressing the highest level of de2-7 EGFR appear to have a significant survival advantage.
To confirm the expression of the de2-7 EGFR in the BaF/3.D2-7 À2 cell line, a Western blot analysis was performed. Following immunoprecipitation with mAb 806, the de2-7 EGFR (B150 kDa) was clearly present as a doublet in lysates of BaF/3.D2-7 À2 cells ( Figure 1b , lane 2) but not in parental BaF/3 lysates ( Figure 1b , lane 1). This doublet has been described by others and represents differential glycosylation (Chu et al., 1997) . To determine whether the de2-7 EGFR was phosphorylated, BaF/3.D2-7 À2 cells lysates were immunoprecipitated with the anti-phosphotyrosine antibody, PY-20. A mAb 806 reactive band was also observed following immunoprecipitation with PY-20 ( Figure 1b, lane 4) , demonstrating that the de2-7 EGFR is constitutively phosphorylated.
Correlation of the de2-7 EGFR expression with survival
To quantify the de2-7 EGFR-mediated survival, BaF/ 3.D2-7 À0 , BaF/3.D2-7 À1 , BaF/3.D2-7 À2 cells were incubated in the absence of IL-3 for 96 h. Since only a low percentage of cells survived, it was necessary to expand the viable cells for 7 days (or 3 days for BaF/3.D2-7 À2 cells) in IL-3 before performing the MTS assay. Under these conditions, virtually none of the parental cells ) or 72 h (BaF/3.D2-7
À2
) and the total cell number, which is directly proportional to the number of surviving cells, was determined by MTS dye. Data are expressed as mean A 490 7s.d. with similar results obtained in three separate assays
The de2-7 EGFR enhances survival RB Luwor et al survived (Figure 1c ), while expression of the de2-7 EGFR clearly enhanced the survival (Figure 1c) . Furthermore, the percentage of cells surviving correlated with the level of de2-7 EGFR expression with the highest expressing cell line, BaF/3.D2-7 À2 , displaying the greatest survival (Figure 1c) . Indeed, BaF/3.D2-7
reached the same cell number as BaF/3.D2-7 À1 in 3 days of IL-3 expansion compared with 7 days. None of the cell lines proliferated in the absence of IL-3.
Signalling molecules associated with survival
To determine which intracellular signalling molecules were associated with the increased survival mediated by de2-7 EGFR, BaF/3.D2-7
À2 cells were treated with specific inhibitors. Cells were cultured in IL-3 overnight in the presence of either AG1478, a specific inhibitor of wt and de2-7 EGFR LY294002, a specific inhibitor of PI3-K; Rapamycin, a specific inhibitor of the mTOR pathway; PD 098059, a specific inhibitor of MAPK Kinase; or DMSO control. Cells were then transferred to IL-3-free media without inhibitors and assayed for survival. Pretreatment with AG1478 decreased survival of BaF/3.D2-7
À2 cells by 71% (Po0.0001), clearly demonstrating that the increased survival is mediated by expression of the de2-7 EGFR (Figure 2a) . Likewise, the survival of BaF/3.D2-7 À2 cells pretreated with LY294002 was reduced by 69% (Po0.001). The survival of BaF/3.D2-7
À2 cells pretreated with rapamycin was reduced by 41% (Po0.0001). In contrast, pretreatment with PD 098059 did not inhibit BaF/3.D2-7 À2 cell survival.
To confirm a role for PI3-K in the de2-7 EGFRmediated survival, we measured total PI3-K activity in the cell lines. BaF/3.D2-7
À2 and BaF/3 cells were grown in the presence or absence of IL-3 for 48 h and assayed for PI3-K activity. The highest activity of PI3-K was observed in the BaF/3.D2-7 À2 cells grown in the presence of IL-3 (Figure 2b ). Removal of IL-3 from this cell line only produced a marginal drop in PI3-K Figure 2 Signalling molecules associated with the survival of BaF/ 3.D2-7 À2 cells. (a) BaF/3.D2-7 À2 cells were cultured overnight in IL-3 media containing either 2 mM AG1478, 10 mM LY294002, 0.2 mM Rapamycin, 50 mM PD 098059 or DMSO control. Cells were then plated in IL-3-free medium without inhibitors for 96 h and the cell survival was assessed as described in Figure 1c À2 cells were cultured in the absence or presence of IL-3-free media for 48 h and the PI3-K activity was determined. Cell lysates were tested at a range of dilutions (1 : 2, 4, 8 and 10), although for clarity the data is only shown at the 1 : 10 dilution. Data is expressed as relative PI3-K activity as determined by ELISA. Similar results were obtained in a second totally independent assay. (c) Parental BaF/3 and BaF/3.D2-7 À2 cells were cultured in IL-3-free media for 24 and 48 h and then stained for phosphorylated Akt. (d) BaF/3.D2-7 À2 cells were cultured in the presence of AG1478 in media with or without IL-3 as indicated and then stained for phosphorylated Akt. (e) Whole-cell lysates from parental BaF/3 and BaF/3.D2-7 À2 cells were prepared following culture in the absence or presence of IL-3-free media for 48 h. Equal amounts of protein separated by SDS-PAGE were immunoblotted for phosphorylated Akt
The de2-7 EGFR enhances survival RB Luwor et al activity (B5%), suggesting that de2-7 EGFR causes sustained activation of PI3-K (Figure 2b ). Even when grown in the presence of IL-3 the level of PI3-K activity was lower in BaF/3 parental cells than BaF/3.D2-7 À2 cells (Figure 2b ), suggesting that the de2-7 EGFR was capable of activating PI3-K by an independent mechanism. In contrast to the BaF/3.D2-7 À2 cell line, the removal of IL-3 from the parental BaF/3 cells for 48 h lead to a further reduction in PI3-K activity (Figure 2b) . Indeed, the PI3-K activity in BaF/3 cells in the absence of IL-3 was approximately 30% lower than BaF/3.D2-7 À2 cells grown without IL-3. Thus, the survival advantage imparted by de2-7 EGFR appears to be mediated via a PI3-K-dependent pathway.
Phosphorylation of Akt is a key event in PI3-Kmediated survival, therefore we analysed the presence of phosphorylated Akt by immunohistochemistry in parental and de2-7-expressing BaF/3 cells incubated in the absence of IL-3 for 24 and 48 h. After 24 h, both cell lines contained cells positive for phosphorylated Akt, however, staining in the BaF/3.D2-7
À2 was more intense, particularly in the nucleus ( Figure 2c , red staining cells). Following 48 h without IL-3, numerous BaF/3.D2-7 À2 cells remained positive for phosphorylated Akt, while staining was virtually absent in the parental cells ( Figure 2c ). The reduced viability of the parental BaF/ 3 cells is also observed at both 24 and 48 h. Treatment of BaF/3.D2-7
À2 cells with AG1478 in the absence of IL-3 for 24 h led to the abrogation of cells positive for phosphorylated Akt ( Figure 2d ) and clearly reduced the cell viability.
We also measured activation of Akt by immunoblotting. The level of phosphorylated Akt was identical in BaF/3.D2-7
À2 and BaF/3 cells when grown in the presence of IL-3 ( Figure 2e ). Consistent with our immunohistochemistry data, while there was robust phosphorylation of Akt in BaF/3.D2-7 À2 cells after 48 h without IL-3, no phosphorylated Akt was detected in BaF/3 parental cells grown in the absence of IL-3 (Figure 2e ). Thus, consistent with our data showing the importance of PI3-K to the de2-7 EGFR-mediated survival, BaF/3.D2-7
À2 displayed sustained levels of phosphorylated Akt.
de2-7 EGFR promotes cell proliferation at low concentrations of IL-3
To establish whether the de2-7 EGFR could promote cell proliferation, BaF/3.D2-7 À2 cells were cultured for 48 h in a suboptimal concentration of IL-3. The parental BaF/3 cells did not proliferate at this low concentration of IL-3, although the majority of cells did survive the 48 h incubation. BaF/3.D2-7
À2 cells not only survived at this low IL-3 concentration but also proliferated (61% increase in cell number) (Figure 3a) . This increase in cell proliferation was completely dependent on de2-7 EGFR as it was inhibited by AG1478 (Figure 3a) . In contrast to the survival assay (Figure 2a) , pretreatment with the LY294002 PI3-K inhibitor was ineffective in blocking the de2-7 EGFR-mediated proliferation (Figure 3b ). The MAPK kinase inhibitor, PD 098059, also had no effect on cell proliferation (Figure 3b) . Thus, the de2-7 EGFR must be able to activate other signalling pathways that stimulate proliferation.
Cell cycle analysis of BaF/3.D2-7 À2 cells
To further discern the effect of de2-7 EGFR, a cell cycle analysis was performed for 62 h after the removal of IL-3 (Table 1) . After 14 h of IL-3 starvation, parental BaF/ 3 and BaF/3.D2-7 À2 cells had similar apoptotic (11 vs 8%, respectively) and G 0 /G 1 (54 and 62%, respectively) profiles. However, 26 h after the removal of IL-3, over 80% of parental BaF/3 cells were apoptotic compared to only 27% of BaF/3.D2-7 À2 cells, confirming that de2-7 EGFR delays apoptosis. In addition, only 4% of parental cells were in S phases compared to 29% of BaF/3.D2-7 À2 cells. By 38 h after the removal of IL-3, 95% of parental BaF/3 cells were apoptotic while only 65% of BaF/3.D2-7 À2 cells were apoptotic. Consistent with our survival data (see Figure 1c) , the percentage of viable cells in BaF/3.D2-7
À2 cells was low but À2 cells were cultured overnight in IL-3 media containing 2 mM AG1478, 10 mM LY294002, 50 mM PD 098059 or DMSO control. Cells were then plated in low IL-3 media for 48 h without inhibitors and the percentage change in cell number calculated as in (a). Data are expressed as percentage change7s.d relative to control cells
The de2-7 EGFR enhances survival RB Luwor et al significantly higher than parental cells (G 0 /G 1 5% for BaF/3.D2-7 À2 cells vs 0% for parental BaF/3 cells) after 62 h of IL-3 starvation.
Consistent with the higher apoptotic rate observed in parental BaF/3 cells, the relative caspase 3 activity was statistically higher in BaF/3 cells compared with BaF/ 3.D2-7
À2 cells (Po0.01) 24 h after IL-3 withdrawal (Figure 4) . Addition of AG1478 during the IL-3 withdrawal had little effect on caspase 3 activation in BaF/3 cells, but caused a significant increase in caspase 3 activity in BaF/3.D2-7 À2 (Po0.01) (Figure 4 ), suggesting that de2-7 EGFR predominantly reduces apoptosis by inhibiting caspase activation. The level of caspase 3 activity in both cell lines was the same when grown in the presence of IL-3 (Figure 4) .
The cell cycle profiles of parental BaF/3 and BaF/ 3.D2-7 À2 cells was also performed at a low IL-3 concentration. Cells were synchronized in G 0 /G 1 by culturing in the absence of IL-3 for 16 h and then restimulated with the low concentration of IL-3. The 16 h time point was based on data obtained from Table 1 , which showed that both cell lines had a similar percentage of G 0 /G 1 and apoptotic cells at this time point. At 10 h after restimulation with IL-3, 78% of parental BaF/3 cells were apoptotic ( Table 2 ), indicating that the majority of cells were already committed apoptosis following the 16 h synchronization. Furthermore, only 3% of BaF/3 cells were actively dividing at this time point. In contrast to these observations, only 13% of BaF/3.D2-7
À2 cells were apoptotic 10 h after restimulation (Table 2 ) and 33% were undergoing cell division. While the apoptotic rate increased at later time points in the BaF/3.D2-7 À2 cells, it always remained significantly lower than the parental cells even at 46 h (22 vs 72%). There was also a significant increase in the number of cells actively dividing in the BaF/3.D2-7
À2
population at 46 h (27 vs 9%). Thus, the increase in BaF/3.D2-7
cell number described at low IL-3 concentrations (Figure 3b ) is the result of decreased apoptosis and increased proliferation. 
Figure 4 Parental BaF/3 and BaF/3.D2-7 À2 cells were cultured in the absence or presence of IL-3-free media for 24 h, cell lysates prepared and caspase 3 activity was determined. In some experiments, cells were also incubated in the presence AG1478 (2 mM). Data are expressed as mean A 490 7s.d. Similar results were obtained in three separate experiments BaF/3 cells expressing the de2-7 and wt EGFR As de2-7 EGFR is invariably coexpressed with the wt EGFR in vivo, the wt EGFR was transfected into the BaF/3.D2-7 À2 cell line. By FACS staining with the EGFR1 antibody directed to the wt EGFR and mAb 806, which is specific for the de2-7 EGFR, we demonstrated the presence of both receptors (Figure 5a ). Cells expressing both de2-7 and wt EGFR (BaF/3.D2-7/wt) were then compared in a survival assay to those expressing either de2-7 or wt EGFR alone. Cells were placed in IL-3-free media containing 10 ng/ml of EGF for 96 h after which time surviving cells were expanded by the addition of IL-3. A significantly greater number of BaF/3.D2-7/wt cells survived compared to cells expressing either receptor alone (Po0.0001) (Figure 5b) .
We then compared the ability of the different BaF/3 cell lines to proliferate at a concentration of IL-3 that was insufficient for proliferation of parental BaF/3 cells. Following 48 h in low IL-3 plus 10 ng/ml EGF, the BaF/ 3.D2-7/wt cell number had increased by 117% compared to 59 and 35% for the BaF/3.wt and BaF/3.D2-7 À2 cells, respectively ( Figure 5c ). Interestingly, the survival and proliferative capabilities of the BaF/3.D2-7/wt cells did not change significantly when the assays were performed without the addition of EGF (data not shown).
Heterodimerization of the de2-7 and wt EGFR
Immunoprecipitation of 35 S-labelled BaF/3.D2-7/wt cells with an antibody specific to the wt EGFR resulted in coprecipitation of the de2-7 EGFR (Figure 6a ). Likewise, immunoprecipitation with an antibody specific for the de2-7 EGFR lead to coprecipitation of the wt EGFR, suggesting that these two EGFRs can spontaneously form heterodimers. To confirm this observation, we performed an immunoprecipitation analysis on 293 cells transiently transfected with differentially tagged de2-7 and wt EGFR. Lysates from 293 cells transfected with both FLAG-and myc-tagged wt EGFR were immunoprecipitated with anti-M2 (i.e. anti-FLAG)-coated beads. Immunoblotting with the 9E10 antibody, which is specific for the myc epitope, clearly demonstrated the presence of coprecipitated myc-tagged wt EGFR in the absence or presence of EGF (Figure 6b, lanes 1 and 2 upper panel) . Thus, the wt EGFR is able to spontaneously form dimers on the cell surface. Immunoblotting of anti-M2 precipitates with the phosphotyrosine-specific antibody, 4G10, demonstrated that phosphorylation of the wt EGFR was largely dependent upon ligand stimulation despite the presence of spontaneous dimers (Figure 6b , lanes 1 Figure 5 Analysis of wt and de2-7 EGFR expression in BaF/3 cells. (a) BaF/3.D2-7
À2
, BaF/3.wt and BaF/3.D2-7/wt cells were stained with either an isotype-matched control antibody (open histograms), the pan-EGFR antibody 528, the wt EGFR-specific antibody EGFR1 or the de2-7 EGFR-specific mAb 806 (black histograms) and then analysed by FACS. (b) BaF/3.wt, BaF/3.D2-7 À2 and BaF/3.D2-7/wt cells were plated in IL-3-free medium containing 10 ng/ml of EGF for 96 h and survival was assessed by MTS assay as described in Figure 1c . Data are expressed as mean A 490 7s.d. with similar results obtained in three separate assays. (c) BaF/3.wt, BaF/3.D2-7 À2 and BaF/3.D2-7/wt cells were plated in low IL-3 media containing 10 ng/ml of EGF for 48 h and proliferation assessed as described in 
Discussion
The level of de2-7 EGFR expression in BaF/3 cells correlated with increased cell survival in the absence of IL-3. Cell cycle analysis demonstrated that de2-7 EGFR expression increased survival following withdrawal of IL-3 by delaying apoptosis. Furthermore, de2-7 EGFR reduced the concentration of IL-3 required to prevent apoptosis and stimulate proliferation. Our results compare favorably with previous studies using the U87MG glioblastoma cell line where the introduction of de2-7 EGFR conferred an increased proliferation and a decrease in apoptosis compared to that of the parental cells (Nagane et al., 1996) . Likewise, transfection of NR6 fibroblasts with the de2-7 EGFR reduced the doubling time of these cells in culture compared to the parental cell line . It was recently reported that transfection of the murine IL-3-dependent pro-B-cell line 32D with de2-7 EGFR results in complete IL-3 independence (Tang et al., 2000) . Given that the authors failed to use an EGFR inhibitor to prove that this effect was due to the expression of de2-7 EGFR, this observation should be viewed with caution. Indeed, they used multiple rounds of IL-3 starvation to select de2-7 EGFR expressing clones, a process that may select for spontaneous mutations leading to IL-3 independence regardless of de2-7 EGFR expression. In contrast, the enhanced survival of our BaF/3.D2-7
À2
cells was completely blocked by the EGFR-specific inhibitor, AG1478. Previously studies have shown that de2-7 EGFR can activate both the PI3-K and MAPK pathways (Montgomery et al., 1995; Moscatello et al., 1996 Moscatello et al., , 1998 . By using a specific inhibitor, we show that PI3-K activation is critical to the enhanced survival mediated by the de2-7 EGFR in BaF/3 cells, further highlighting the significance of this pathway in de2-7 EGFR function. Interestingly, the MAPK appears to have no role in de2-7 EGFR-mediated survival in BaF/3. Activation of PI3-K leads to phosphorylation of Akt, which in turn activates a number of survival proteins including Bad and mTOR (Hidalgo and Rowinsky, 2000) . Two recent publications demonstrated that transfection of the de2-7 EGFR into U87MG glioma cells, which endogenously express wt EGFR, leads to phosphorylation of Akt via PI3-K mechanism (Narita et al., 2002; Klingler-Hoffmann et al., 2003) . This activation of Akt was shown to be critical for the growth advantage mediated by the de2-7 EGFR. Our studies in BaF/3 cells demonstrate for the first time that the de2-7 EGFR can induce and sustain phosphorylation of Akt in the absence of the wt EGFR. Furthermore, inhibition of mTOR, which is downstream of Akt signalling, also partially inhibited the de2-7 EGFR-mediated survivial. Activation of Akt can also lead to downstream phosphorylation of the proapoptotic protein BAD, causing its disassociation from Bcl-X L , which in turn allows Bcl-X L to exert its antiapoptotic activity (Coffer et al., 1998; Downward, 1998; Datta et al., 1999) primarily through the modulation of caspase activity (Burri et al., 1999; Weinmann et al., 1999) . Consistent with this scenario, activation of Akt in BaF/3 expressing the de2-7 EGFR leads to a reduction in caspase 3 activity. Interestingly, Bcl-X L was found to be upregulated in U87MG glioma cells following transfection with de2-7 EGFR (Nagane et al., 1996) . Therefore, both the PI3-K/Akt/Bcl-X L and PI3-K/Akt/mTOR pathways have a role in the enhanced survival mediated by de2-7 EGFR in BaF/3 cells.
Interestingly, PI3-K and MAPK had no role in BaF/ 3.D2-7
proliferation at low IL-3 concentrations, suggesting that other signalling pathways may be Figure 6 Heterodimerization and trans-phosphorylation of the wt EGFR with the de2-7 EGFR. (a) BaF/3.D2-7/wt cells were labelled for 4 h with 500 mCi/ml of Tran 35 S-label, lysed immunoprecipitated with EGFR1 or mAb 806 as indicated. Proteins were separated by SDS-PAGE, dried and exposed to X-ray film to detect radiolabelled proteins. (b) 293 cells were transiently transfected with FLAG-tagged wt EGFR in combination with myc-tagged wt (lane 1 and 2) or de2-7 EGFR (lane 3 and 4) for 2 days. Cells were then washed and starved for 2 h before stimulation with EGF (200 ng/ml) for 10 min. The cells were then lysed and the total lysates subjected to immunoprecipitation with anti-M2 (FLAG) antibody-conjugated beads. Proteins were resolved by SDS-PAGE and immunoblotted with the anti-myc antibody 9E10 to detect coprecipitated receptors or the anti-phosphotyrosine antibody 4G10 activated by de2-7 EGFR. One possible mechanism is the activation of the signal transducers and activators of transcription (STAT) family of proteins, STAT3 and STAT5 by IL-3, that mediates proliferation and survival in many hematopoietic cells (Reddy et al., 2000) . A previous study reported the activation of STAT1, 3 and 5 by ligand activation of EGFR (David et al., 1996) . Therefore, the combination of de2-7 EGFR signalling and IL-3R activation by low concentrations of IL-3 may be sufficient to trigger proliferation of BaF/3.D2-7
cells. This is not observed when only the de2-7 EGFR or the IL-3R is activated by low levels of IL-3 independently. Hence, similar to the wt EGFR, it is likely that the de2-7 EGFR stimulates multiple signalling pathways to mediate different cellular responses.
We (Walker et al., 1998a, b) and others (Riese et al., 1995 (Riese et al., , 1996a have also utilized the BaF/3 cell line to examine whether EGFR family members could abrogate IL-3 dependency. Like BaF/3.D2-7
À2 cells, BaF/3 cells transfected with wt EGFR and stimulated with ligand can proliferate at IL-3 concentrations insufficient to induce proliferation of the parental cell line (Walker et al., 1998a) . Interestingly, the EGF-dependent survival of BaF/3 cells expressing the wt EGFR was completely abrogated by PD 098059, implicating MAPK as a keysignalling molecule in survival (Walker et al., 1998b) . As MAPK was not important in survival of de2-7 EGFRexpressing BaF/3 cells, we postulate that the de2-7 and wt EGFR may mediate some cellular responses such as survival though different signalling pathways. Differential signalling between the de2-7 and wt EGFR has been reported previously (Lorimer and Lavictoire, 2001) . In this study, activation of MAPK by the de2-7 EGFR was PI3-K dependent, whereas MAPK activation by the wt receptor was PI3-K independent.
The coexpression of wt EGFR with other ErbB family members in BaF/3 cells leads to enhanced survival or proliferation when stimulated with a host of ligands (Riese et al., 1995 (Riese et al., , 1996a . We also observed similar enhanced survival when de2-7 and wt EGFR were coexpressed in BaF/3 cells. Indeed, this enhanced survival and proliferation appeared to be the result of de2-7/wt EGFR dimer formation in both BaF/3 and 293 cells, as suggested by the coprecipitation of both receptors. In contrast to other ErbB interactions, this interaction occurred in the absence of ligand activation demonstrating that de2-7 EGFR can directly activate the wt EGFR. To our knowledge, this is the first time de2-7 and wt EGFR dimerization has been described. By extending our studies to focus on other downstream signalling proteins, we hope to gain a greater understanding of de2-7 and wt EGFR interactions, which will provide new insights into how de2-7 EGFR enhances tumorigenicity of glioma cells.
Materials and methods
Generation of cell lines and cell culture
The murine pro-B-lymphocyte cell line, BaF/3, was transfected with a retroviral vector containing the de2-7 EGFR gene (Nishikawa et al., 1994) . Parental and transfected BaF/3 cells were maintained in RPMI 1640 (GibcoBRL, Grand Island, NY, USA), 10% FCS (CSL, Melbourne, Australia), 2 mM glutamine (Sigma Chemical Co., St Louis, MO, USA), penicillin/streptomycin (GibcoBRL, Grand Island, NY, USA) and 10% WEHI 3BD À -conditioned medium as a source of IL-3. The generation of BaF/3 cells expressing the wt EGFR has been described previously (Walker et al., 1998a) . The vector pRc/RSV, which contains wt EGFR cDNA, was cotransfected with a hygromycin-resistance vector (pTK/ Hyg) into BaF/3 cells expressing the de2-7 EGFR to generate BaF/3 cells expressing both receptors.
Selection of cells expressing high de2-7 EGFR levels
Following transfection with the de2-7 EGFR gene, BaF/3 cells were cultured in IL-3-free RPMI 1640 containing 10% FCS for 96 h. Surviving cells were expanded by the addition of 10% of IL-3-conditioned media and the process was repeated. Cells from the original transfected population, first round of selection and second round of selection were designated BaF/3.D2-7
À0
, BaF/3.D2-7
À1 and BaF/3.D2-7 À2 , respectively.
Antibodies and growth factors
The anti-phosphotyrosine monoclonal antibodies PY-20 and 4G10 were from New England Biolabs (New England Biolabs, Beverly, MA, USA) and Upstate Biotechnology (Upstate Biotechnology, Lake Placid, NY, USA), respectively. The mouse antibody EGFR1, which is specific for the wt EGFR (Waterfield et al., 1982; Nishikawa et al., 1994) , was from DAKO (DAKO Corporation, Carpinteria, CA, USA). The pAkt1 rabbit polyclonal antibody, which recognizes phosphorylated Akt at Ser 473 was from Santa Cruz (Santa Cruz Biotechnology, La Jolla, CA, USA). The anti-EGFR mouse antibody 528 (Masui et al., 1984) and the anti-de2-7 EGFRspecific mouse antibody mAb 806 (Luwor et al., 2001) were produced in our Biological Production Laboratory, LICR, Melbourne, Australia. Recombinant human EGF was from Auspep (Auspep Pty Ltd, Victoria, Australia).
Immunoprecipitations and Western blot analysis
After overnight culturing without IL-3, BaF/3 cells were washed and lysed in extraction buffer (30 mM HEPES, 150 mM NaCl, 10 mM NaF, 1% Triton X-100, Protease inhibitor cocktail set 1 (Calbiochem, San Diego, CA, USA), pH 7.4). Lysates were clarified by centrifugation, appropriate antibodies added for and the resultant immune complexes precipitated with protein-A-Sepharose beads (AMRAD Biotech, Melbourne, Australia). Proteins were separated by SDS-PAGE and blotted onto PVDF membrane (Millipore Corporation, Bedford, MA, USA). After blocking with 5% human serum albumin (HSA), filters were probed with specific antibodies and analysed using enhanced chemiluminescence (Amersham Pharmacia Biotech UK Ltd, Buckinghamshire, England) following incubation with HRP-conjugated secondary antibodies.
Immunoprecipitations and Western blot analysis of 293 cells 293 cells were obtained from ATCC (American Type Culture Collection, Bethesda, MD, USA) and were grown as above. Transient transfections were performed using FuGENEt 6 (Roche Molecular Biochemicals, Indianapolis, IN, USA). Construction of N-terminal-tagged wt and de2-7 EGFR plasmids has been previously described (Zhu et al., 2003 Cells were labelled for 4 h with 500 mCi/ml of Tran 35 S-label (ICN Biomedicals, Irivine) in RPMI without methionine/ cysteine, lysed and immune complexes were precipitated. Proteins were separated by SDS-PAGE using a 4-20% gel, air dried and exposed to X-ray film to detect radiolabelled proteins.
FACS analysis of receptor expression
Cells were incubated with 5 mg/ml of primary antibody, in PBS containing 1% HSA for 30 min at 41C. After washing, cells were incubated a further 30 min with FITC-coupled goat antimouse antibody at 41C (Calbiochem, San Diego, CA, USA). Cells were then analysed on an Epics Elite ESP (Beckman Coulter, Hialeah, FL, USA).
Inhibitors
LY294002, PD 098059 and Rapamycin were all purchased from Sigma (Sigma Chemical Co., St Louis, MO, USA). AG1478 (Levitzki et al., 1991) , an EGFR-specific inhibitor was a kind gift from Professor Alex Levitzki (The Hebrew University of Jerusalem, Israel).
Cell proliferation and survival assays
Proliferation assay: cells were incubated overnight in IL-3 with chemical inhibitors or the appropriate DMSO control. Cells were then washed in media without IL-3, plated onto 96-well plates at a concentration of 1.5 Â 10 4 /well and incubated in a final concentration of 0.125% WEHI 3BD À -conditioned medium. This concentration of IL-3 was sufficient to promote survival of parental BaF/3 cells for 48 h but insufficient to stimulate proliferation. After 48 h, viable cell number was determined using the MTS proliferation assay (Promega Corporation, Madison, WI, USA). Percentage increase in viable cells was calculated using the formula: (A 490 (48 h)ÀA 490 (0 h)) Â 100/(A 490 (0 h)).
Survival assay: cells were placed on 96-well plates in the absence of IL-3 for 96 h before an equal volume of 20% IL-3-conditioned media was added to expand viable cells. This was done as the absolute number of surviving cells was very low. After cell expansion in IL-3, the relative cell number was determined using the MTS assay. When grown in 10% IL-3-conditioned media, the final cell number was directly proportional to the number of surviving cells (data not shown).
Immunohistochemistry of BaF/3 cells
After culturing parental BaF/3 and BaF/3.D2-7 À2 in the absence of IL-3 for 24 and 48 h, cells were collected by cytospin and fixed in acetone for 10 min. Cells were then stained with the phosphorylated Akt antibody, incubated with anti-rabbit-HRP (Silenus, Melbourne, Australia) and then exposed to 3-amino-9-ethylcarbozole (AEC) substrate (0.1 M acetic acid, 0.1 M sodium acetate, 0.02 M AEC (Sigma Chemical Co., St Louis, MO, USA)) in the presence of hydrogen peroxide. Sections were counterstained with hematoxylin and mounted.
Determination of total PI3-K activity
BaF/3 and BaF/3.D2-7
À2 cells were grown in the presence or absence of IL-3 for 48 h. Cells were lysed with extraction buffer (see above) and immunoprecipitated with an excess of PI3-K antibody (Upstate Biotechnology, Waltham, MA, USA). The PI3-K activity was determined by a competitive ELISA that measures PI(3,4,5)P3 production using the instructions supplied by the manufacturer (Echelon, Salt Lake City, UT, USA).
Cell cycle analysis
Cell cycle analysis was performed as described previously (Wright et al., 1999) with minor modifications. Cells were grown in the absence of IL-3 for 16 h, then cultured in either 0.125% IL-3 or continued in 0% IL-3 for time points up to 62 h. At each time point, cells were washed in PBS, fixed in icecold 70% methanol and then stained with propidium iodide (PI) solution, (4 mM sodium citrate, 0.1% Triton X-100, 1/50 DNase-free RNase A (Boehringer Mannheim GmbH, Mannheim, Germany), 50 mg/ml PI (Sigma Chemical Co., St Louis, MO, USA)). The percentage of cells in G 0 /G 1 , S, G 2 M and in the apoptotic phase was determined by FACS analysis. Caspase 3 activity was determined by the CaspACEt colorimetric Assay system (Promega Corporation, Madison, WI, USA) according to the manufacturer's instructions.
